<DOC>
	<DOCNO>NCT00557427</DOCNO>
	<brief_summary>The study pilot study adolescents 12 - 18 year age mild moderate depression randomize receive either hypericum 250mg twice daily fluoxetine 10mg daily increase 20mg daily 1 week option increase 40mg daily 4 week . Patients treat total 8 week . Efficacy measure use CDRS-R , BDI-II CGI scale . Safety parameter include blood test , urinalysis ECG .</brief_summary>
	<brief_title>Hypericum v Fluoxetine Mild Moderate Adolescent Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Signed informed consent Adolescents age 12 18 year Patients meet criterion mild moderate depression accord DSMIV scale Physical laboratory examination baseline compatible study criterion ECG baseline compatible study criterion Score least 40 Children 's Depression Rating Scale Revised ( CDRSR ) baseline Patients psychosis , bipolar disease , schizophrenia significant developmental disorder Patients epilepsy Patients history alcohol substance abuse past year Initiation psychotherapy behavioral therapy 2 month prior screen study . Patients previously fail respond SSRI 's SRNI 's Patients treat antidepressant within 2 week screen ( 4 week fluoxetine ) Patients contraindication take either Remotiv fluoxetine take medication contraindicate take Remotiv fluoxetine</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>mild moderate depression accord DSM-IV scale</keyword>
</DOC>